5α-还原酶抑制剂和 α-阻滞剂使用者的前列腺癌风险和预后影响：系统评价和荟萃分析。
Prostate Cancer Risk and Prognostic Influence Among Users of 5-Alpha-Reductase Inhibitors and Alpha-Blockers: A Systematic Review and Meta-Analysis.
机构信息
National Institute of Clinical Research, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.
Department of Urology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.
出版信息
Urology. 2020 Nov;145:216-223. doi: 10.1016/j.urology.2020.05.105. Epub 2020 Jul 31.
We systematically assessed the effect of 5-alpha-reductase inhibitors (5-ARIs) and/or alpha-blockers use on prostate cancer (CaP) incidence and outcomes, including CaP pathologic progression, CaP-specific mortality, and all-cause mortality. 5-ARIs but not alpha-blockers decreased risk of overall CaP, low grade CaP (Gleason < 7), and delayed CaP pathologic progression. Both 5-ARIs and alpha-blockers had no significant impact on risk of high grade CaP (Gleason ≥ 7), CaP-specific mortality, or all-cause mortality. Our result suggested that finasteride should be given for at least 4 years if used for preventing CaP.
我们系统地评估了 5α-还原酶抑制剂（5-ARIs）和/或α-受体阻滞剂的使用对前列腺癌（CaP）发病率和结局的影响，包括 CaP 病理进展、CaP 特异性死亡率和全因死亡率。5-ARIs 而非 α-受体阻滞剂降低了总体 CaP、低级别 CaP（Gleason<7）和 CaP 病理进展的风险。5-ARIs 和 α-受体阻滞剂对高级别 CaP（Gleason≥7）、CaP 特异性死亡率或全因死亡率的风险没有显著影响。我们的结果表明，如果使用非那雄胺预防 CaP，则至少应使用 4 年。
Zotero 插件